Michael R Hayden bought $481K of AbCellera Biologics (ABCL)
Executed Aug 12, disclosed Aug 14, 2 days later.
Over the 21 trading sessions from the disclosed entry session (Aug 14), the stock returned +3.0% (delay-adjusted); from the execution session (Aug 12), +13.4%. Derived: entry at the session's open, exit at the close 20 sessions later.
Michael R Hayden (Director) filed 2 Form 4 reports in the trailing twelve months (2 purchases, 0 sales), most often in Ionis Pharmaceuticals, Inc. (IONS). Across 2 priced purchase filings, the average 21-session return was +14.6% from execution and +8.8% from disclosure (delay-adjusted; derived). The largest single filing was $1.1M of IONS (20,000 sh across 2 lots, as filed), executed Jul 30.
Healthcare · AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the Unit…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→